(Reuters) -The U.S. Food and Drug Administration said on Friday that it will convene a panel of experts on January 22, 2026, to review an request by Swedish Match USA, a unit of Philip Morris International, to market its ZYN nicotine pouches as lower-risk alternatives to cigarettes.

The advisory committee will examine modified-risk applications for 20 ZYN products, each sold in 3-mg and 6-mg strengths.

The FDA in January 2025 cleared the same 20 products for sale after reviewing them under its premarket system for new tobacco products, allowing them to remain on the U.S. market.

That decision did not allow Swedish Match to claim the products reduce disease risk.

Swedish Match USA now wants permission to use the statement: “Using ZYN instead of cigarettes puts you at a lower risk of mou

See Full Page